Warren S. Levy , MD, FACC

Warren Levy, MD web

Warren S. Levy, MD is an interventional cardiologist who also serves as President and Chief Medical Officer of Virginia Heart. Through invasive and non-invasive procedures, he treats patients suffering from a variety of cardiac conditions. He is board certified in cardiovascular disease and internal medicine and serves as a Clinical Assistant Professor of Medicine and Cardiology at Georgetown University School of Medicine.  “I take great pride in the care and compassion that the Virginia Heart family provides to our patients and our community,” he said. “The greatest joy and honor we have as physicians is to make a significant impact upon the lives of our patients and their families by improving their quality of life, their health and ultimately extending life through life saving measures.”

Dr. Levy earned his medical degree with honors from the George Washington University School of Medicine, going on to complete his residency and fellowships there in general and interventional cardiology.

To “walk the walk” of good cardiovascular care, Dr. Levy is an avid runner and skier—as long as his knees hold up. He cherishes time with his family, who bring him much pride and fulfillment.

Affiliations & Awards


  • Top Doctor | Northern Virginia Magazine
  • Alpha Omega Alpha Medical Honor Society 

Leadership Positions

  • President & Chief Medical Officer | Virginia Heart
  • Member, Steering Committee | MedAxiom
  • Former Medical Director, Non-Invasive Cardiovascular Services | Virginia Hospital Center
  • Former Member, Medical Executive Committee | Virginia Hospital Center
  • Former Chair, Clinical Risk Management Committee | Virginia Hospital Center
  • Former Member, Medical Staff Executive Committee & Admissions Committee | George Washington University Medical Center

Other Languages Spoken

  • French

Hospital Affiliations

  • Virginia Hospital Center
  • Inova Alexandria Hospital
  • Inova Fair Oaks Hospital
  • Inova Fairfax Hospital
  • Reston Hospital Center


  • Levy WS, Katz RJ, Ross AM:  Limited Prognostic Value of Sub-maximal Exercise Testing  Following Non-Q Wave MI.  (Abst.) Circulation 1987; 76, IV-170.  (Presented at the 60th Annual Scientific Sessions, American Heart Association, November 1987.)
  • Morganroth J, Horowitz LN for the Encainide VT Research Group Levy, WS co- investigator)  Efficacy and Safety of Encainide in Life-Threatening Ventricular       Tachyarrythmias.  (Abst.)  Circulation 1987; 76, IV-368.
  • Levy WS, Katz RJ, Ruffalo RL, Leiboff RH, Wasserman AG:  Methionine Potentiates the Vasodilatory Effects of Nitroglycerin.  (Abst.)  J Am Col Card 1988; 11, 43A.  (Presented at the 37th Annual Scientific Sessions, American College of Cardiology, March 1988.)
  • Levy WS, Simon GL, Ross AM, Schulof RS, Rios JC: Clinically Silent Cardiac Abnormalities in Patients with HIV Infection.  (Abst.)  IV International Conference on AIDS, June, 1988, Stockholm, Sweden.
  • Levy WS, Varghese PJ, Anderson DW, Leiboff  RH, Orenstein JM, Virmani R, Bloom S: Myocarditis Diagnosed by Endomyocardial Biopsy in Human Immunodeficiency Virus Infection with Cardiac Dysfunction.  Am J Cardiol 1988; 62:658 – 659.
  • Levy Ws, Katz RJ, Ruffalo RL, Lieboff RH, Wasserman AG:  Potentiation of the Hemodynamic Effects of Acutely Administered Nitroglycerin by Methionine.  Circulation 1988;78: 640 - 645.
  • Levy WS, Simon GL, Rios JC, Ross Am:  Prevalence of Cardiac Abnormalities in Human Immunodeficiency Virus Infection.  Am J Cardiol 1989, 63: 86-89.
  • Levy WS, Simon GL, Rios JC, Ross AM:  Cardiac Abnormalities in Patients with Human Immunodeficiency Virus Infection.  (Abst.)  Circulation; 1988, 78:II-458.  (Presented at the 61st Annual Scientific Sessions, American Heart Association, November 1988.)
  • Levy WS, Katz RJ, Wasserman AG:  Methione Reverse Tolerance to Transdermal Nitroglycerin.  (Abst.)  J Am Coll. Cardiol 1989, 13:230A.  (Presented at the 38th Annual Scientific Sessions, American College of Cardiology, March 1989.)
  • The Encainide-Ventricular Tachycardia Study Group:  Treatment of Life-Threatening Ventricular Tachycardia with Encainide Hydrochloride in Patients with Left Ventricular Dysfunction.  (Levy WS:  Co-Investigator) Am J Cardiol 1988; 62:571-575.
  • Levy WS, Katz RJ, Buff L, Wasserman AG:  Nitroglycerin Tolerance is modified by Angiotensin Converting Enzyme Inhibitors (Abst.) Circulation 1989;80: II-214.  (Presented at the 62nd Annual Scientific Sessions, American Heart Association, November, 1989.)
  • Levy WS, Katz RJ, Wasserman AG:  Methionine Restores the Venodilative Response to Nitroglycerin after the Development of Tolerance. J Am Coll. Cardiol 1991;17:474-479.
  • Katz RJ, Levy WS, Wasserman AG:  Prevention of Nitrate Tolerance with Angiotensin Converting Enzyme Inhibitors. Circulation 1991;83: 1271-1277.
  • The Cardiac Arrhythmia Suppression Trial II Investigators:  Effect of the Antiarrhythmic Agent Moricizine on Survival after Myocardial Infarction.  (Levy, WS:  Co-Investigator)  New England Jour Med. 1992;327:227-223.
  • The GUSTO Investigators: An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction.  (Levy, WS:  Co-Investigator) New England Jour Med. 1993; 329:673-82.
  • O’Connor FG, Levy WS, Oriscello RG, Wilder RP:  Asymptomatic Aortic Insufficiency in a Runner.  The Physician and Sports Medicine 1995; 23:33-42.

"The greatest joy and honor as a physician is when we have the opportunity to make a significant impact upon the lives of our patients and their families -- both when life saving measures are needed and in quality of life."

- Dr. Warren S. Levy